Why telmesartan is not given preopratively

Reading Document

Medical Text Search

telmisartan ARB angiotensin receptor blocker preoperative withholding perioperative

Medical Text Search

ACE inhibitors ARBs preoperative hypotension refractory anesthesia surgery

GradeResponse

Why Telmisartan (and ARBs in General) Are Withheld Preoperatively

Telmisartan is an Angiotensin II Receptor Blocker (ARB). The core reason it is withheld before surgery relates to its mechanism of action and how that interacts with anesthesia and surgical stress.

Mechanism-Based Explanation

Telmisartan blocks AT1 receptors, preventing angiotensin II from exerting its vasoconstrictive and aldosterone-stimulating effects. Under normal conditions, this lowers blood pressure. However, in the perioperative setting, this becomes dangerous:

The RAAS is a critical compensatory mechanism during surgery. Induction of anesthesia, fluid shifts, blood loss, and positive-pressure ventilation all cause vasodilation and reduced preload. Normally, the body compensates by activating the renin-angiotensin-aldosterone system (RAAS) to maintain vasoconstriction and blood pressure.
With telmisartan on board, this compensatory RAAS response is blocked. The body cannot mount an adequate vasoconstrictive response, resulting in refractory intraoperative hypotension — hypotension that does not respond well to standard vasopressors like ephedrine and phenylephrine.
Standard vasopressors are relatively ineffective because they often work indirectly via the RAAS or adrenergic pathways that have reduced efficacy when AT1 receptors are blocked. Vasopressin (terlipressin/vasopressin analogues) may be needed instead.

Clinical Evidence

According to Management of Elevated Blood Pressure and Hypertension (p. 74):

"Some studies suggest that continued use of ACE inhibitors is associated with a higher risk of peri-operative hypotension and subsequent end-organ damage including kidney injury, myocardial infarction, and stroke."

"In the Prospective Randomized Evaluation of Preoperative Angiotensin-Converting Enzyme Inhibition (PREOP-ACEI) trial, transient pre-operative interruption of ACE inhibitor therapy was associated with a decreased risk of intra-operative hypotension."

"A subsequent systematic review also showed a decreased risk of intra-operative hypotension with withholding ACE inhibitors/ARBs before surgery."

Why Telmisartan is Particularly Concerning

Among ARBs, telmisartan has the longest half-life (~24 hours) and the highest lipophilicity, giving it prolonged duration of action. This means:

Even if withheld the morning of surgery, residual drug effect may persist
It is recommended to withhold telmisartan at least 24–48 hours before elective surgery

Summary Table

Concern	Explanation
Refractory hypotension	RAAS blockade prevents compensatory vasoconstriction under anesthesia
End-organ damage	Hypotension → AKI, MI, stroke
Poor vasopressor response	Standard agents (ephedrine, phenylephrine) less effective
Long half-life	Telmisartan's ~24h t½ means prolonged effect even after last dose
Fluid shifts	Surgery-related blood/fluid loss exacerbates hypotension risk

Current Recommendation

Most anesthesia guidelines recommend withholding ACE inhibitors and ARBs (including telmisartan) on the day of surgery, particularly for elective procedures. Some guidelines suggest stopping 24 hours prior. However, this should be weighed against the risk of uncontrolled hypertension in the perioperative period, and the decision is individualized based on indication (e.g., heart failure patients may need to continue).

This is a shared conversation. Sign in to Orris to start your own chat.